AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03164499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual counselling on lifestyles
Description: Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
Study NCT03164499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional group counselling on lifestyles
Description: Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment.
Study NCT00266279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Capecitabine
Description: Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21
Study NCT02046993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart phone telemonitoring HBP + enhanced usual care
Description: Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
Study NCT02046993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart phone telemonitoring HBP + enhanced usual care
Description: Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
Study NCT01462669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 50mg Ezogabine/retigabine
Description: A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Study NCT01462669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 100mg Ezogabine/retigabine
Description: A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Study NCT01462669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 200mg Ezogabine/retigabine
Description: A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Study NCT01462669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 400mg Ezogabine/retigabine
Description: A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Study NCT03749538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation session.
Description: Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
Study NCT03749538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation session.
Description: Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
Study NCT04368780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Progressive Muscle Relaxation Combined With Music
Description: The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
Study NCT01695356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 290-400 nm sunscreen
Description: A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
Study NCT02832830 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
Study NCT02832830 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fractionated RT
Description: external beam Radiotherapy of the involved spinal bone metastasis
Study NCT01074034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Therapy Assessment-B301 investigational device
Description: Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
Study NCT04005248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV IgG test
Description: An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
Study NCT00523458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz or nevirapine
Description: Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.
Study NCT00523458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz or nevirapine
Description: Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.
Study NCT01695356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 290-800 nm sunscreen
Description: A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
Study NCT02430857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Manuel osteopathic treatment of the spine
Study NCT03095729 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological tests
Description: A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
Study NCT04406428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NKI followed by EBD
Description: Needle-knife incision therapy followed by endoscopic bougie dilation
Study NCT03413462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
Study NCT03413462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-25
Description: HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
Study NCT03413462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HS-25
Description: Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
Study NCT00738179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP worn nightly
Study NCT00738179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care of cardiovascular risk factors
Study NCT03686605 — intervention group
Intervention type: OTHER
Intervention: Thai version of the Edmontom Symptom Assessment System (ESAS)
Description: Screening and diagnostic questionaire for depression
Study NCT01025882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01025882 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Given as a single fraction
Study NCT04230928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 \& 10. Participants will learn to track carbohydrate intake
Study NCT04230928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard DPP-GLB diet
Description: Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, \& 10
Study NCT04230928 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard DPP-GLB program modules
Description: Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
Study NCT04230928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard DPP-GLB program modules
Description: Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
Study NCT03982732 — intervention group
Intervention type: BIOLOGICAL
Intervention: Boostrix-IPV
Description: Receipt of Boostrix IPV at three different gestational time periods
Study NCT00469430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxim and metronidazol
Description: iv administration for at least 24 h
Study NCT01792037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Study NCT05800886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and tea consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
Study NCT05800886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and coffee consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
Study NCT05800886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and warm water consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
Study NCT05800886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: The first mobilization and oral intake of the patients in the control group started at the 8th hour.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
Study NCT01792037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
Study NCT01792037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT01807299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
Study NCT01807299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega 3
Description: Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
Study NCT01807299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Study NCT01807299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Training
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegFN
Description: type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT01582035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT00404287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin
Study NCT03057015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study NCT01789684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Provider Intervention
Description: Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
Study NCT03800238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Delivery Format
Description: Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
Study NCT03800238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Delivery Format
Description: Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
Study NCT00681889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 10 Patients will receive treatment (Ranibizumab)
Study NCT04406675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological test
Description: neuropsychological test
Study NCT03221686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
Study NCT03221686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: High quality protein supplement 14 days pre-operatively and post-operatively.
Study NCT00939536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Tartrate Tablets 10 mg
Study NCT00939536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets 10 mg
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 28 weeks, high dose, TID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 40 weeks, QD
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 4 weeks, low dose TID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 16 weeks, according to label
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 28 weeks, according to label
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 40 weeks, high dose, TID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, very high dose, BID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, standard dose, BID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 48 weeks, according to label
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 40 weeks, according to label
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, high dose, TID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 28 weeks, QD
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 16 weeks, QD
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 weeks, according to label
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, standard dose, BID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, high dose, BID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207217
Description: 28 weeks, high dose BID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, high dose, TID
Study NCT01132313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 4 weeks, high dose, TID